Request Trial
16 July 2025VideosAmericasMichael Shuster, Goodwin Law | Erica LoRe, Invivyd | Guy Birkenmeier, New England Biolabs

WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US

LSPN experts from Goodwin Law, Invivyd, and New England Biolabs discuss the challenges of patent eligibility under 35 U.S.C. § 101 in life sciences innovation. The session explores strategies to address obstacles arising from recent court decisions and USPTO guidelines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
5 ways the USPTO director is changing US innovation
24 December 2025   John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.
Americas
Mirum targets generics in quartet of suits over liver treatment
22 December 2025   Biopharma company and two others have taken action against numerous defendants over proposed generic versions of Livmarli, Mirum’s core revenue driver.
Americas
WATCH: Enabling success — overcoming §112 in the new era of life sciences patents
22 December 2025   Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.


Editor's picks

SCOTUS shuts the door on Entresto ‘after-arising technology’ review
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

Editor's picks

Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025
Europe
Biotech cleared to make biosimilar of $6bn treatment after landmark ruling
25 November 2025
Americas
INTA votes in new 2026 president at Florida leadership meeting
20 November 2025

More features

UPC: A review of 2025 and what to expect in 2026
From Edwards to Insulet: Three key medical device cases of 2025
5 ways the USPTO director is changing US innovation
Mirum targets generics in quartet of suits over liver treatment
WATCH: Enabling success — overcoming §112 in the new era of life sciences patents
WATCH: Clinical trials and their impact on patentability in Europe
WATCH: “Try and see” – an underestimated standard for obviousness before the EPO?
SCOTUS shuts the door on Entresto ‘after-arising technology’ review